A SINGLE-BLIND, RANDOMIZED, ESCALATING MULTIPLE DOSE STUDY (PART 1) AND A SEVEN TREATMENT CROSSOVER BIOAVAILABILITY STUDY (PART 2) OF LT-NS001 AND NAPROXEN ADMINISTERED IN HEALTHY SUBJECTS
Completed
- Conditions
- Chronische pijn zoals bij Rheumatische arthritisChronic pain
- Registration Number
- NL-OMON31529
- Lead Sponsor
- ogical Therapeutics, Inc
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 36
Inclusion Criteria
Healthy subjects
Male, 18-70, inclusive (Part 1)
Male/Female, 45-70, inclusive(Part 2), famales must be post menopausal
Exclusion Criteria
Pathology for example Hepatitis B, Cancer or HIV/AIDS.
If you have participated in any other drug investigation within 90 days preceding the start of this study or if you have donated blood within 60 days preceding start of this study or loss of blood of similar volume.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method